Aripiprazole 5 mg: Potential supply issue
The supplier of aripiprazole, Sandoz, has advised of a supply issue for their aripiprazole tab 5 mg.
The issue is caused by manufacturing issues relating to COVID-19.
There are currently low levels of stock available from the supplier and wholesalers.
What Sandoz is doing
Sandoz is working on securing an alternative product to ensure New Zealanders can continue to access this medicine. The alternative product will likely need to be supplied under section 29 of the Medicines Act.
There are sufficient stock levels of the 10 mg, 15 mg, 20 mg and 30 mg aripiprazole tablet strengths. We are aware that these tablets are unable to be split in order to get a 5 mg dose.
We will provide more information about the availability of alternative 5 mg stock during the week starting 3 August 2020.
Last updated: 31 July 2020